TAK-360 placebo (same excipients as TAK-360)
Sponsors
Takeda Development Center Americas Inc.
Conditions
Idiopathic Hypersomnia (IH)Narcolepsy with Cataplexy (NT1)Narcolepsy without Cataplexy (NT2)
Phase 2
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)
RecruitingCTIS2024-517712-29-00
Start: 2025-05-27Target: 48Updated: 2026-01-08
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
RecruitingCTIS2024-517711-70-01
Start: 2025-12-04Target: 12Updated: 2025-11-21
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Not yet recruitingCTIS2025-522587-33-00
Target: 22Updated: 2026-06-22